Summary
Salivary and plasma concentrations of bromocriptine (BCT), a dopamine agonist, were measured by gas chromatography in four patients with Parkinson's disease. All the patients had been on mono-therapy with BCT for years, and during the 3 weeks prior to the investigation they received constant but individually different dosage regimens. Paired samples of pure, parotid, serous saliva and of blood were collected hourly during one eight hour dose interval. The concentrations of BCT in saliva were very low and there was a ten-fold range in the areas under the salivary and plasma concentration/time curves. It is concluded that in clinical practice measurement of BCT in saliva is not suitable for exact estimation of the plasma concentration of BCT. Using the measured salivary pH and the plasma BCT concentration, calculations based on the Henderson-Hasselbalch equation showed that the assumption of about 99% plasma protein binding of BCT best fited the observed concentrations of BCT in saliva.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Anavekar SN, Saunders RH, Wardell WM, Shoulson I, Emmings FG, Cook CE, Gringeri AJ (1978) Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clin Pharmacol Ther 24: 629–637
Carlson AJ, Crittenden AL (1910) The relation of ptyalin concentration to the diet and to the rate of secretion of the saliva. Am J Physiol 26: 169–177
Diamant B, Diamant H, Holmstedt B (1957) The salivary secretion in man under the influence of intravenously infused acetyl-beta-methylcholine iodide. Arch Int Pharmacodyn Ther 111: 86–97
DiGregorio GJ, Piraino J, Ruch E (1978) Diazepam concentrations in parotid saliva, mixed saliva and plasma. Clin Pharmacol Ther 24: 720–725
Eckert H, Kiechel JR, Rosenthaler J, Schmidt R, Schreier E (1978) In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds, Springer-Verlag, Berlin Heidelberg New York, pp 719–803
Friis ML, Grøn U, Larsen N-E, Pakkenberg H, Hvidberg EF (1979) Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease. Eur J Clin Pharmacol 15: 275–280
Kangas L, Allonen H, Lammintausta R, Salonen M, Pekkarinen A (1979) Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. Acta Pharmacol Toxicol 45: 20–24
Larsen N-E, Öhman R, Larsson M, Hvidberg EF (1979) Determination of bromocriptine in plasma: Comparison of gas chromatography, mass fragmentography and liquid chromatography. J Chromatogr 174: 341–349
Mucklow JC, Bending MR, Kahn GC, Dollery CT (1978) Drug concentration in saliva. Clin Pharmacol Ther 24: 563–570
Pearce I, Pearce JMS (1978) Bromocriptine in parkinsonism. Br Med J 1: 1402–1404
Price P, Debono A, Parkes JD, Marsden CD, Rosenthaler J (1978) Plasma bromocriptine levels, clinical and growth hormone responses in parkinsonism. Br J Clin Pharmacol 6: 303–309
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Friis, M.L., Johnsen, T., Larsen, N.E. et al. Bromocriptine concentration in saliva and plasma after long-term treatment of patients with Parkinson's disease. Eur J Clin Pharmacol 18, 171–174 (1980). https://doi.org/10.1007/BF00561586
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561586